Anne VanLent Net Worth

The estimated Net Worth of Anne Vanlent is at least $95 Thousand dollars as of 9 May 2019. Ms. Vanlent owns over 5,000 units of Vaxart Inc stock worth over $24,424 and over the last 20 years she sold VXRT stock worth over $0. In addition, she makes $70,571 as Independent Director at Vaxart Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. VanLent VXRT stock SEC Form 4 insiders trading

Anne has made over 2 trades of the Vaxart Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of VXRT stock worth $50,000 on 9 May 2019.

The largest trade she's ever made was exercising 7,500 units of Vaxart Inc stock on 13 January 2010 worth over $249,900. On average, Anne trades about 329 units every 90 days since 2004. As of 9 May 2019 she still owns at least 25,983 units of Vaxart Inc stock.

You can see the complete history of Ms. Vanlent stock trades at the bottom of the page.

Anne VanLent biography

Anne M. VanLent is Independent Director of the Company. She is currently President of AMV Advisors, which provides corporate strategy and financial consulting services to emerging growth life sciences companies. From May 2002 to April 2008, Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly-traded pharmaceutical company. From July 1997 to October 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Ms. VanLent currently serves as a director and chairs the audit committees of Aegerion Pharmaceuticals, Inc., Ocera Therapeutics, Inc., and Applied Genetics Technologies Corporation (AGTC), all of which are publicly-traded companies. During the past five years, Ms. VanLent also served as a director of Onconova Therapeutics, Inc. where she also served as Audit Chair, and as a director of Integra Life Sciences Corporation, a publicly-traded biotechnology company, until May 2012. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College. Ms. VanLent’s extensive leadership and finance experience, and her extensive experience serving as a board member, audit committee member and audit committee chair of numerous public companies in the life sciences industry, led to the conclusion that she should serve on the Company’s Board of Directors.

What is the salary of Anne VanLent?

As the Independent Director of Vaxart Inc, the total compensation of Anne VanLent at Vaxart Inc is $70,571. There are 6 executives at Vaxart Inc getting paid more, with Wouter Latour having the highest compensation of $747,711.

How old is Anne VanLent?

Anne VanLent is 72, she's been the Independent Director of Vaxart Inc since 2013. There are no older and 13 younger executives at Vaxart Inc.

What's Anne VanLent's mailing address?

Anne's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.

Insiders trading at Vaxart Inc

Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo, and Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.

What does Vaxart Inc do?

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.

Complete history of Ms. Vanlent stock trades at Applied Genetic Technologies Corp, Integra Lifesciences Corp, Onconova Therapeutics Inc, Vaxart Inc, and Trevi Therapeutics

Vaxart Inc executives and stock owners

Vaxart Inc executives and other stock owners filed with the SEC include:

• Wouter Latour,
  Chairman of the Board
• Cezar Andrei Floroiu M.B.A.,
  CEO, Pres, Principal Financial Officer & Director
• Dr. Sean N. Tucker,
  Sr. VP & Chief Scientific Officer
• Margaret A. Echerd,
  Sr. VP & Principal Accounting Officer
• Sean Tucker,
  Chief Scientific Officer
• Margaret Echerd,
  Principal Accounting Officer, Vice President, Controller
• Anne VanLent,
  Independent Director
• Michael Finney,
  Independent Director
• Robert Yedid,
  Lead Independent Director
• Todd Davis,
  Independent Director
• Karen Wilson,
  Independent Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Andrei Floroiu,
  Chief Executive Officer, Principal Financial Officer, Director
• Edward B. Berg,
  Sr. VP & Gen. Counsel
• John M. Harland M.B.A., CPA,
  Consultant
• Dr. James F. Cummings M.D.,
  Chief Medical Officer
• Dr. Rajesh Kapoor Ph.D.,
  Sr. VP of Quality
• Dr. Richard M. Schwartz,
  Sr. VP of Technical Operations
• Brant Biehn,
  Sr. VP of Bus. Operations
• Shaily Jaini Garg,
  Sr. VP of Clinical Devel. & Project Management
• Julie M Cherrington,
  Director
• Edward B Berg,
  SVP, General Counsel
• John M Harland,
  Chief Financial Officer
• Richard J Markham,
  Director
• Geoffrey F Cox,
  Director
• John P Richard,
  Director
• Phillip E Lee,
  Chief Financial Officer
• David E. Wheadon,
  Director
• James F. Cummings,
  Chief Medical Officer
• W. Mark Watson,
  Director
• Elaine J Heron,
  Director
• Steven Lo,
  President, Chief Exec Officer
• Fuad Ahmad,
  Interim CFO